

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re U.S. Patent No. 7,411,050

Issued: August 12, 2008

To: Dirk M. Anderson

Assignee: Immunex Corporation

For: MONOCLONAL BLOCKING ANTIBODY TO
HUMAN RANKL

MAIL STOP HATCH-WAXMAN PTE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

POWER OF ATTORNEY BY APPLICANT

The undersigned, a representative authorized to sign on behalf of the Applicant and Parent Company (Amgen Inc.) of the assignee owning all of the interest in this patent, verifies that Immunex Corporation is the assignee of the entire right, title, and interest in U.S. Patent No. 7,411,050 (the '050 patent) by virtue of an assignment from the inventor to Immunex Corporation, recorded in the U.S. Patent and Trademark Office (for parent application US Application No. 08/995,659 to which U.S. Patent No. 7,411,050 claims priority) at Reel 010732, Frame 0297 on March 27, 2000. Immunex Corporation is a wholly owned subsidiary of Amgen Inc. To the best of the undersigned's knowledge and belief, title to the '050 patent is in the assignee.

The undersigned hereby grants power of attorney to the attorneys associated with Customer No. 22,852, both jointly and separately as attorneys with full power of

substitution and revocation to prosecute the application for patent term extension of the '050 patent and to transact all business in the Patent and Trademark Office connected therewith.

Please send all future correspondence concerning this application for patent term extension to Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P., Customer No. 22,852, at the following address:

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413



Dated: Aug. 31, 2010

By: Stuart L. Watt

Name: Stuart Watt

Title: Vice President, Law

Applicant: Amgen Inc.